OVID THERAPEUTICS INC

Ovid Therapeutics shares fall 4% as the company reinforces its focus on rare neurological treatments, while peers invest in longevity diagnostics.

Ovid Therapeutics sees a 4.66% rise amid market volatility, offering cautious optimism as its rare neurological pipeline looks to hit key milestones and push toward a 52‑week high.

Ovid Therapeutics stock edges up at $2.36, after a near‑20% dip, with a stable 200‑day SMA of $2.33. Investors eye rare‑neurology pipeline milestones and partnership prospects for potential upside.